Pharvaris N.V. (PHVS) Stock Score, Valuation & Financial Research

Pharvaris N.V. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PHVS

Pharvaris N.V. does not currently have a complete Wall Street Score. The stored market price is USD 30.75. These figures are a research snapshot, not a buy or sell recommendation.

What Pharvaris N.V. does

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Pharvaris is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of novel, oral bradykinin B2 receptor antagonists to treat bradykinin-mediated diseases, with future revenue dependent on the successful clinical development, regulatory approval, and commercialization of its product candidates.

Products and services

  • The company is developing a pipeline of oral bradykinin B2 receptor antagonists, including deucrictibant, for the treatment of hereditary angioedema (HAE) and acquired angioedema (AAE).

Customer types

Patients with hereditary angioedema (HAE); Patients with acquired angioedema (AAE-C1INH).

Suppliers, materials and equipment

  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials and drug candidates. Source

Competitors and product-market comparisons

  • Takeda Pharmaceutical Company Limited — Competes in the market for hereditary angioedema treatments. Source
  • CSL Behring — Competes in the market for hereditary angioedema treatments. Source
  • BioCryst Pharmaceuticals, Inc. — Competes in the market for hereditary angioedema treatments. Source

Business strengths to evaluate

  • Proprietary platform for oral bradykinin B2 receptor antagonists Source

Business risks and research considerations

  • History of operating losses and expectation of continued losses Source
  • Dependence on third-party manufacturers for clinical supply Source
  • Regulatory risks associated with clinical trial success and approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PHVS financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 30.75
Market capitalization:
2.15B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -192.2M
Free cash flow:
USD -153.75M
Cash:
USD 356.57M
Total debt:
USD 754.77K
EPS:
USD -3.02

What stands out

  • Free cash flow is USD -153.75M, negative for the stored period.
  • The balance sheet shows USD 356.57M of cash versus USD 754.77K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 355.81M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PHVS

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can PHVS fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is PHVS likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for PHVS to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of PHVS's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-12.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research PHVS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.